Microport Neuroscientific

MicroPort NeuroScientificFormerly known as “MicroPort NeuroTech”), as a member of Microport Scientific Corporation (00853.HK, MicroPort), has been researching and developing industry leading neuro-interventional medical devices since 2002. We are dedicated to providing universal stroke treatment solutions to patients and physicians worldwide. Since the approval of our first product - APOLLO™ intracranial stent system in 2004, we have been developing a comprehensive product portfolio which covers three major neurovascular disease areas, specifically Hemorrhagic Stroke, Intra and Extracranial Atherosclerotic Stenosis, and Acute Ischemic Stroke. As of Aug 2024, we had 21 products approved by NMPA, and 4 products admitted to the NMPA’s Innovative Medical Device Special Review and Approval procedure (known as the “Green Path”). Our products are available in over hospitals nationwide, providing safe and effective stroke solutions for more than patients accumulatively. Meanwhile, we have a leading global strategy and international expansion. a total of 8 products of the Group were approved for marketing in 23 overseas countries or regions. Headquartered in Shanghai Zhangjiang Science City, NeuroTech employs over 400 people worldwide. In our pursuit of excellence, we aspire to improve the lives of patients, physicians and our employees, and to create innovative solutions for neurovascular stroke disorders. Together, our efforts will continue to impact the health and well-being of people globally. For more information, please visit